| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447010 | European Journal of Cancer | 2011 | 7 Pages |
Abstract
Everolimus-induced OU is a frequent, recurrent and sometimes harmful complication. A dose effect relationship is displayed. Its daily management remains challenging. OU represents a key issue in the compliance of mTOR inhibitors.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Charles Ferté, Angelo Paci, Meriem Zizi, Daniel Barrios Gonzales, Aicha Goubar, Carlos Gomez-Roca, Christophe Massard, Tarek Sahmoud, Fabrice André, Jean-Charles Soria,